{
    "eid": "2-s2.0-85021255614",
    "title": "Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial",
    "cover-date": "2017-09-01",
    "subject-areas": [
        {
            "$": "Orthopedics and Sports Medicine",
            "@code": "2732"
        },
        {
            "$": "Endocrinology",
            "@code": "2712"
        }
    ],
    "keywords": [
        "ANTIRETROVIRAL THERAPY",
        "BONE MINERAL DENSITY",
        "CLINICAL TRIALS",
        "DXA",
        "HIV"
    ],
    "authors": [
        "Jennifer F. Hoy"
    ],
    "citedby-count": 43,
    "ref-count": 40,
    "ref-list": [
        "Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review",
        "Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system",
        "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial",
        "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents",
        "Antiretroviral drugs for treatment and prevention of HIV infection in Adults: 2016 recommendations of the international antiviral society-USA Panel",
        "Bone, fracture and frailty",
        "Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen",
        null,
        "Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss",
        "HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development",
        "RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men",
        "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-Naive HIV-1-infected individuals",
        null,
        "Initiation of antiretroviral therapy in early asymptomatic HIV infection",
        "Prevalence of and risk factors for low bone mineral density in untreated HIV infection: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial",
        "Standardization of bone mineral density at femoral neck, trochanter and ward's triangle",
        "Universal standardization of bone density measurements: A method with optimal properties for calibration among several instruments",
        "The diagnosis of osteoporosis",
        "Lumbar spine and proximal femur bone mineral density, bone mineral content, and bone area: United States, 2005-2008",
        "Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis",
        "International Society for Clinical Densitometry",
        "WHO Scientific Group on the Assessment of Osteoporosis at the Primary Health Care Level Summary Meeting Report",
        "Continuous antiretroviral therapy decreases bone mineral density",
        "Vienna, Austria R Foundation for Statistical Computing",
        "Recommendations for evaluation and management of bone disease in HIV",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials",
        "Changes in bone mineral density after initiation of antiretroviral treatment with Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir",
        "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202",
        "Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study",
        "The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis",
        "Use of oral corticosteroids and risk of fractures",
        "Changes in bone mineral density with age in men and women: A longitudinal study",
        "Stable bone density in HAART-treated individuals with HIV: A meta-analysis",
        "The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-na\u00efve HIV-1-infected patients",
        "Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial",
        "Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy",
        "Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals",
        "Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy",
        "Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?",
        "Low bone mineral density in patients with well-suppressed HIV infection: Association with body weight, smoking, and prior advanced HIV disease"
    ],
    "affiliation": [
        {
            "affiliation-city": "Minneapolis",
            "affilname": "University of Minnesota Twin Cities",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lima",
            "affilname": "Asociaci\u00f3n Civil Impacta Salud y Educaci\u00f3n",
            "affiliation-country": "Peru"
        },
        {
            "affiliation-city": "Brussels",
            "affilname": "Centre Hospitalier Universitaire Saint Pierre, Brussels",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Birmingham",
            "affilname": "University Hospitals Birmingham NHS Foundation Trust",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Sydney",
            "affilname": "St. Vincent's Hospital Sydney",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "University of California, San Francisco",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Minneapolis",
            "affilname": "VA Midwest Health Care Network",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Melbourne",
            "affilname": "Monash University",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Johannesburg",
            "affilname": "University of the Witwatersrand, Johannesburg",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "Rio de Janeiro",
            "affilname": "Projeto Pra\u00e7a Onze",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Pune",
            "affilname": "Institute of Infectious Diseases",
            "affiliation-country": "India"
        }
    ],
    "funding": [
        "National Institute of Allergy and Infectious Diseases",
        "National Institute of Allergy and Infectious Diseases"
    ]
}